Literature DB >> 26292950

Epidemiology and Clinical Evolution of Liver Cirrhosis in Singapore.

Pik Eu Chang1, Guan Wee Wong, James Wq Li, Hock Foong Lui, Wan Cheng Chow, Chee Kiat Tan.   

Abstract

INTRODUCTION: Liver cirrhosis is a common cause of morbidity and mortality and an important burden on the healthcare system. There is limited literature on liver cirrhosis in Singapore. We aimed to describe the epidemiology and clinical characteristics of cirrhotic patients seen in an ambulatory setting in a tertiary referral centre.
MATERIALS AND METHODS: This is a retrospective observational cohort study of cirrhotic patients attending the ambulatory clinic of Singapore's largest tertiary hospital over 5 years. Cirrhosis was diagnosed on characteristic radiological features and/or histology. Aetiology of cirrhosis was determined by history, serology, biochemistry and/or histology. Data on decompensation events and death were retrieved from computerised hospital records.
RESULTS: The study included 564 patients with median follow-up of 85 months. Mean age was 60.9 ± 12.5 years with 63.8% males. Main aetiologies of cirrhosis were chronic hepatitis B (CHB) (63.3%), alcohol (11.2%), cryptogenic (9%) and chronic hepatitis C (CHC) (6.9%). CHB was the predominant aetiology in Chinese and Malays whereas alcohol was the main aetiology in Indians. CHC cirrhosis was more common in Malays than other races. Majority had compensated cirrhosis with 76.8%/18.3%/5%; Child-Pugh A/B/C respectively. Decompensation events occurred in 155 patients (27.5%) and 106 of them (18.8%) died. Diagnosis of cirrhosis via surveillance ultrasound was associated with improved 10-year survival. Age at diagnosis, portal vein thrombosis, Child-Pugh class and decompensation within 1 year of diagnosis were independent predictors of mortality.
CONCLUSION: CHB is the primary cause of liver cirrhosis in Singapore. The major aetiologies of cirrhosis vary amongst the different ethnic groups. Cirrhotics with advanced age, portal vein thrombosis, poorer liver function and early decompensation have a higher mortality risk.

Entities:  

Mesh:

Year:  2015        PMID: 26292950

Source DB:  PubMed          Journal:  Ann Acad Med Singapore        ISSN: 0304-4602            Impact factor:   2.473


  12 in total

Review 1.  Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission.

Authors:  Shiv K Sarin; Manoj Kumar; Mohammed Eslam; Jacob George; Mamun Al Mahtab; Sheikh M Fazle Akbar; Jidong Jia; Qiuju Tian; Rakesh Aggarwal; David H Muljono; Masao Omata; Yoshihiko Ooka; Kwang-Hyub Han; Hye Won Lee; Wasim Jafri; Amna S Butt; Chern H Chong; Seng G Lim; Raoh-Fang Pwu; Ding-Shinn Chen
Journal:  Lancet Gastroenterol Hepatol       Date:  2019-12-15

2.  Clinical Yi-guan decoction for liver cirrhosis: A protocol for systematic review and meta analysis.

Authors:  Xingyao Hu; Guangbin Shang; Jie Zhang; Zhong Chen; Liu Fu; Jun Li; Xiaonan Lu
Journal:  Medicine (Baltimore)       Date:  2021-04-02       Impact factor: 1.817

3.  Public awareness and knowledge of liver health and diseases in Singapore.

Authors:  Chee-Kiat Tan; George Boon-Bee Goh; Jin Youn; Jacques Chak-Kwan Yu; Shikha Singh
Journal:  J Gastroenterol Hepatol       Date:  2021-03-30       Impact factor: 4.369

Review 4.  Perioperative Care of Patients With Liver Cirrhosis: A Review.

Authors:  Naeem Abbas; Jasbir Makker; Hafsa Abbas; Bhavna Balar
Journal:  Health Serv Insights       Date:  2017-02-24

5.  Modelling NAFLD disease burden in four Asian regions-2019-2030.

Authors:  Chris Estes; Henry L Y Chan; Rong N Chien; Wan-Long Chuang; James Fung; George Boon-Bee Goh; Tsung H Hu; Jee-Fu Huang; Byoung K Jang; Dae W Jun; Jia H Kao; Jin-Woo Lee; Han-Chieh Lin; Kathryn Razavi-Shearer; Wai-Kay Seto; Grace L-H Wong; Vincent W-S Wong; Homie Razavi
Journal:  Aliment Pharmacol Ther       Date:  2020-03-04       Impact factor: 8.171

Review 6.  An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia.

Authors:  Michael R Charlton; Altaf Alam; Akash Shukla; Bekhbold Dashtseren; Cosmas Rinaldi Adithya Lesmana; Davadoorj Duger; Diana Alcantara Payawal; Do Duy Cuong; Ganbolor Jargalsaikhan; Ian Homer Yee Cua; Jose Decena Sollano; Karam Romeo Singh; Kaushal Madan; Khin Maung Win; Khin Pyone Kyi; Kyaw Soe Tun; Mohd Salih; Mukul Rastogi; Neeraj Saraf; Pham Thi Thu Thuy; Pham Tran Dieu Hien; Rino Alvani Gani; Rosmawati Mohamed; Tawesak Tanwandee; Teerha Piratvisuth; Wattana Sukeepaisarnjaroen; Win Naing; Zahid Yasin Hashmi
Journal:  J Gastroenterol       Date:  2020-07-14       Impact factor: 7.527

7.  Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population.

Authors:  Xiao-Lin Liu; Qin Pan; Rui-Nan Zhang; Feng Shen; Shi-Yan Yan; Chao Sun; Zheng-Jie Xu; Yuan-Wen Chen; Jian-Gao Fan
Journal:  World J Gastroenterol       Date:  2016-11-28       Impact factor: 5.742

Review 8.  Liver Disease in Singapore.

Authors:  Mark Muthiah; Chern H Chong; Seng G Lim
Journal:  Euroasian J Hepatogastroenterol       Date:  2018-05-01

9.  High expression of FAM13A was associated with increasing the liver cirrhosis risk.

Authors:  Yingai Zhang; Shunlan Wang; Chan Wang; Jingchuan Xiao; Shufang Zhang; Hailong Zhou
Journal:  Mol Genet Genomic Med       Date:  2019-01-02       Impact factor: 2.183

10.  Clinical validation of the chronic liver disease questionnaire for the Chinese population in Singapore.

Authors:  Pik-Eu Chang; Hiang-Keat Tan; Yean Lee; Stephanie Fook-Chong; Pei-Yuh Chia; Nurshifa Shaik-Hussain; Hwei-Ling Lee; Fazila Aloweni
Journal:  JGH Open       Date:  2019-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.